
Colgate Palmolive to introduce more brands in India from its global portfolio
FMCG major Colgate-Palmolive (India) plans to introduce more brands here from the company's global portfolio to upscale its play in India -- one of the drivers for its growth, MD & CEO Prabha Narasimhan said on Monday.
The company, having presence in the country with two brands - Colgate and Palmolive - currently operates in the oral care and personal care, and is in "active ongoing conversation" with the parent firm for expanding the portfolio.
"We are very excited about what all we can do in India, both with our existing brands and portfolio, and with what we can do with the things that we can bring in from the globe. We have tremendous support from our global counterparts in terms of their excitement about what we can achieve in India," Narasimhan told PTI.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
When Alone - Wrap Foil Around Your Doorknob (Here's Why)
Life Hacks 101
About the Palmolive brand, which is currently operating in the personal care space with a premium body wash and hand wash range, Narasimhan said, they have tremendous potential and grow at 20 to 30 per cent CAGR.
When asked as whether
Colgate-Palmolive India L
Ltd (CPIL) will extend the brand Palmolive in new segments, she added she would rather focus on introducing more brands.
Live Events
"Actually, more than extending the brand Palmolive, we have a lot of products portfolio that is available globally. We are looking to see what of that product portfolio can legitimately be brought into India and make sense for the Indian consumer, and leverage the strengths that
Colgate Palmolive India
has. So that's a very active ongoing conversation," she added.
CPIL, which has been operating in India for the last 88 years, currently contributes around 4 to 5 per cent of the global revenue of the Midtown Manhattan, New York City-based multinational consumer products major Colgate-Palmolive Company.
According to Narasimhan, "in the coming years, the contribution of India will certainly increase."
India, with its over 1.4 billion population, is always a "central part" of Colgate's global strategy and is now among five markets, which are called out as being the drivers of growth.
"If you listen to our global CEO... who was speaking even recently at a conference where he talked about the fact that India will add more middle-class people in the next few years than any other country in the world, and therefore represents a tremendous opportunity for us," she said.
Besides, on the channel side, CPIL, as per its strategy, is also extending its play into the fast-growing e-commerce channels, by adding more digital-first brands, exclusive to online sales channels. It has launched Colgate Purple and Max Fresh Sensories range, mouthwash sticks, which is for a small audience in the market.
"We have quite a few, and we have a pipeline of many more," she added.
However, she also added that traditional trade, which is neighbourhood kirana stores, is actually the bulk of CPIL's business and critical for the company. It has a "tremendous relationship" with its distributors, many of whom have been with it for decades.
Earlier in May, All India Consumer Products Distributors Federation (AICPDF), an umbrella body of FMCG distributors pan-India, had called for the suspension of the purchase of all products of CPIL in Maharashtra, alleging deep discounting by it in favour of quick commerce channels.
However, Narasimhan said there is "enough room" for all the channels in the market.
Talking about the trend of consumers becoming more health-conscious, seeking better products and organic options, Narasimhan said consumers buy benefits and CPIL has the right science to deliver all of these benefits.
Recently, the oral care segment has witnessed heightened competition, where several brands have launched their toothpaste based on ingredients derived from traditional ayurveda and organic options.
"Indian consumers are sensible enough to know that they look for a benefit, they find products that deliver to that benefit, and that's our primary job," she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
20 minutes ago
- Mint
Phillip Capital flags growth risks for Dixon Tech amid rising competition; lowers target price to ₹9085
Dixon Technologies share price in focus: Shares of Dixon Technologies tumbled 2.5% in Wednesday's trade (June 25), falling to ₹ 14,585 apiece, even as the broader Indian stock market traded in positive territory. This drop in one of the country's leading EMS (Electronics Manufacturing Services) companies came after global brokerage firm Phillip Capital downgraded its estimates for Dixon, citing rising competition in the mobile phone assembly space. According to the brokerage, Dixon's largest client, Motorola, has started outsourcing domestic volumes to Karbonn, which currently accounts for 25% of Motorola's monthly volume, a figure expected to rise to 35% by June. As part of its diversification strategy, Motorola has been actively expanding its supplier base. Motorola contributes approximately 40% of Dixon's mobile phone volumes but nearly 72% of its mobile phone revenues. Dixon had significantly benefited from Motorola's market share gains in the Indian smartphone market in CY24 compared to CY23. When Motorola was a smaller player in CY23, Dixon handled its entire manufacturing. As Motorola has achieved scale, it has started outsourcing some of its volumes to Karbonn to diversify its supply chain. It is worth noting that Karbonn itself is a recipient of mobile phone PLI and, therefore, can be cost-competitive in the mobile phone assembly space. The brokerage said the company's exports have ramped up in the last few months, but domestic volume gain by Karbonn means Dixon's YoY growth from Motorola will be capped at c.15% at best. In addition to Motorola, Dixon's second-largest client, Longcheer, has also begun diversifying its supply chain. While Dixon's volumes from Longcheer have grown over the past year, the client outsourced a small portion (2%) to Karbonn in May CY25. Though currently modest, Phillip Capital believes this could scale up quickly, following a pattern similar to Motorola's shift. Motorola initially outsourced just 1–2% of its volumes to Karbonn in February CY25, which jumped to 30% by May. On a more positive note, Dixon and Vivo entered into a 51:49 joint venture (JV) for mobile phone manufacturing in December CY24. The JV, which is currently awaiting regulatory approval, is expected to begin contributing to Dixon's topline by FY27. Management anticipates that the JV will handle two-thirds of Vivo India's mobile phone volumes. Based on a proportional volume-to-value ratio, the JV could generate revenue of ₹ 160 billion at optimal utilization, with Dixon's share estimated at ₹ 80 billion. Phillip Capital has lowered its revenue, EBITDA, and PAT estimates for Dixon Technologies for FY27 by 4%, 6%, and 9%, respectively, to reflect the intensifying competition in the mobile phone assembly space. Dixon shares its PLI (Production Linked Incentive) benefits with its mobile phone clients, which is currently offset by favorable Net Working Capital (NWC) terms. However, once the mobile phone PLI scheme ends, the brokerage expects Dixon's NWC days to trend toward 35+, in line with peers—Foxconn's stood at 40+ in CY24—which could lead to a declining RoCE trajectory. Factoring this in, Phillip Capital has also revised its valuation multiple, cutting the PE multiple from 50x to 45x FY27 EPS of ₹ 202, resulting in a revised target price of ₹ 9,085, down from the earlier target of ₹ 11,077. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.


Mint
20 minutes ago
- Mint
HDB Financial Services day 1 Live: GMP, subscription status, price, date to review. Apply or not to this HDFC Bank arm?
HDB Financial Services IPO: The initial public offering (IPO) of HDB Financial Services Limited has hit the Indian primary market today. The public issue will remain open until 27 June 2025. The HDFC Bank arm company has declared the HDB Financial Services IPO price band at ₹ 700 to ₹ 740 per equity share. The book build issue is proposed for listing on the BSE and the NSE. The initial public offer aims to raise ₹ 12,500 crore from this public issue, out of which ₹ 2,500 crore is aimed at issuing fresh shares. The rest of ₹ 10,000 crore is reserved for the offer for sale (OFS). According to market observers, company shares are available in the grey market well ahead of the HDB Financial Services IPO subscription opening. They said that one share of HDB Financial Services Limited is available at a premium of ₹ 75 in the grey market today. BNP Paribas, JM Financial, BofA Securities India, Goldman Sachs India, HSBC Securities, IIFL Capital Services, Jefferies India, Morgan Stanley India, Motilal Oswal Investment Advisors, Nomura India, Nuvama Wealth Management, UBS Securities India are the book-running lead managers of the HDB Financial IPO. At the same time, MUFG Intime India Private Limited (Link Intime) is the official registrar for the issue. By 11:06 AM on day 1 of bidding, the public issue had been subscribed 0.10 times. The retail portion of the public issue had been booked 0.10 times, whereas the NII segment had been subscribed 0.14 times. 1] HDB Financial Services IPO GMP: According to market observers, the company's shares are available at a premium of ₹ 75 in today's grey market. 2] HDB Financial Services IPO price: The company has declared the price band for the book-build issue at ₹ 700 to ₹ 740 per equity share. 3] HDB Financial IPOHDB Financial Services IPO date: The public issue has opened today and will remain open until 27 June 2025. 4] HDB Financial Services IPO size: The company aims to raise ₹ 12,500 crore, of which ₹ 10,000 crore is reserved for OFS and the rest, ₹ 2,500 crore, is aimed through fresh shares. Infographic: Courtesy mintgenie 5] HDB Financial Services IPO lot size: A bidder can apply in lots, and one lot of the book build issue comprises 20 company shares. 6] HDB Financial Services IPO allotment date: The most likely date to finalise the share allocation is 30 June 2025. 7] HDB Financial IPO registrar: MUFG Intime India Private Limited (Link Intime) has been appointed the official registrar of the book build issue. 8] HDB Financial Services IPO lead managers: BNP Paribas, JM Financial, BofA Securities India, Goldman Sachs India, HSBC Securities, IIFL Capital Services, Jefferies India, Morgan Stanley India, Motilal Oswal Investment Advisors, Nomura India, Nuvama Wealth Management, UBS Securities India have been appointed lead manager of the public issue. 9] HDB Financial Services IPO listing date: The most likely date for listing shares is 2 July 2025. 10] HDB Financial Services IPO review: KR Choksey Securities has given a 'subscribe' tag to the public issue, saying, "HDB's initial issue is priced at 3.4x TTM P/B (considered equity raise for calculating TTM BV) compared to the peer average of 4.4x TTM P/B. We believe the issue is attractively priced, considering its parentage, peer group ROA average and its growth potential. We assign a "SUBSCRIBE" rating to the initial issue of the HDB Financial Service." Sharekhan has also assigned a 'subscribe' tag to the initial offer, saying, "The company is valued at an FY25 price-to-book ratio of ~3.2x/~3.4x at post-issue capital at the lower price band & upper price band respectively, which is reasonable as compared to its peers considering the growth and return ratio profile. Strong parentage and much smaller size than its core peer (Bajaj Finance) provide a long runway for growth. Additionally, a favourable macro environment will be a tailwind for the sector in the near to medium term. We expect healthy listing gains and remain assertive from a medium to long-term perspective." Apart from these, Kunvarji Finstock, Aditya Birla Money, Bajaj Broking, Canara Bank Securities, Centrum Wealth Management, Nirmal Bang, SBI Capital Securities, etc., have also been assigned a 'subscribe' tag to the HDB Financial Services IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.


Mint
23 minutes ago
- Mint
China 1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs
New Delhi [India], : Indian pharmaceutical and biotech sectors have started witnessing tangible benefits from the global shift away from China, as early signs of the China 1 strategy materialising emerge, according to a recent Goldman Sachs report. Some pharmaceutical and biotech companies report that they have started witnessing the conversion of earlier enquiries and Requests for Quotations into pilot projects and small contracts. The 'China Plus One' strategy is a business technique in which corporations diversify their manufacturing and supply chains by expanding into countries other than China while still keeping a presence in China. The report was prepared based on the outcome of the '2nd annual India CRO/CDMO trip' event in Bengaluru and Hyderabad. The credit rating firm, in its equity report, added that Indian companies witnessed a major uptick in RFQs from global clients looking to diversify supply chains away from China. While these developments indicate progress, the report also noted that large-scale financial gains from these shifts will take time, possibly a three- to five-years. "After seeing a significant influx of enquiries/ RFQs over the past 1-1.5 years, management of some companies like Syngene, Neuland, Divi's, etc. have now started highlighting instances of conversion of RFQs to pilot projects/contracts, although large financial benefits will still take time to materialise," the report added. The report further added, "We expect the geographic supply chain diversification theme to play out over a 3-5 year period, if not more." The report also speaks about BIOSECURE Act of the United States, an evolving policy which directs to reduce American dependence on Chinese biotech suppliers. "While investor discussion around the BIOSECURE Act is relatively light as there have been limited updates on this topic, most corporates acknowledged that their clients are actively building strategies to reduce their dependence on China," Goldman Sachs added in the report. Interestingly, the report observes that this trend is being led by large pharmaceutical and biotech companies, which are more willing and able to bear the switching costs involved. Contrary to the big players, smaller companies, in the US and Europe, are still hesitant due to funding constraints and the capital-intensive nature of moving suppliers. While there is little immediate investor focus on the act due to limited updates, corporates across the sector confirmed that their clients are proactively preparing for a post-China sourcing strategy.